Locally Advanced dMMR/MSI-H Rectal Cancer
ANABAnaptyBio IncCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Jemperli/Dostarlimab (PD-1 Antagonist) in Locally Advanced dMMR/MSI-H Rectal Cancer. The expected timing is based on the latest available company guidance and may change.
11/04/25:- Pivotal Ph2 AZUR-1 in untreated dMMR/MSI-H rectal cancer; topline data expected H2 2026. 03/03/26:- AZUR-1 Ph2 rectal cancer trial retains 2026 topline guidance; granted FDA Breakthrough Therapy and CNPV voucher. 05/12/26:- AZUR-1 Phase 2 rectal cancer data timing reiterated as H2 2026 with prior FDA designations unchanged.
Verification
Confirm timing and program details against the company announcement or filing.